Drugs / Eicosapentaenoic acid free fatty acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03806426 | Dec 2018 → Jun 2024 | classic familial adenomatous polyposis | S.L.A. Pharma AG | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eicosapentaenoic acid free fatty acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03806426 ↗ |
| Known as | EPA-FFA | “Eicosapentaenoic acid free fatty acid (EPA-FFA)” NCT03806426 ↗ |